CSF from Parkinson disease Patients Differentially Affects Cultured Microglia and Astrocytes

BMC Neuroscience

Volumn 11, Issue , 2010, Pages

  Schiess, Mya C ^a   Barnes, Jennifer L ^a   Ellmore, Timothy M ^a   Poindexter, Brian J ^a   Dinh, Kha ^a   Bick, Roger J ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN;

ADULT; AGED; ARTICLE; ASTROCYTE; BRAIN TISSUE; CELL CULTURE; CELL DEATH; CELL FUNCTION; CELL GROWTH; CELL STRUCTURE; CEREBROSPINAL FLUID; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN CELL; MALE; MICROGLIA; OUTCOME ASSESSMENT; PARKINSON DISEASE; PROTEIN BLOOD LEVEL; PROTEIN DENATURATION; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SHAPE; COMPARATIVE STUDY; IMMUNOLOGY; LEWY BODY; METABOLISM; PATHOLOGY; PHYSIOLOGY; PROTEIN CEREBROSPINAL FLUID LEVEL; TUMOR CELL LINE;

ALPHA-SYNUCLEIN; ASTROCYTES; CELL DEATH; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SHAPE; CELLS, CULTURED; CEREBROSPINAL FLUID PROTEINS; HUMANS; LEWY BODIES; MICROGLIA; PARKINSON DISEASE;

EID: 78649385929     PISSN: None     EISSN: 14712202     Source Type: Journal    
DOI: 10.1186/1471-2202-11-151     Document Type: Article

References (35)

1. Blum-Degen D, Müller T, Kuhn W, Gerlach M, Przuntek H, Riederer P. Interleukin-1β and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients. Neurosci Lett 1995, 202:17-20. 10.1016/0304-3940(95)12192-7, 8787820.
2. Mogi M, Harada M, Kondo T, Riederer P, Nagatsu T. Interleukin-2 but not basic fibroblast growth factor is elevated in parkinsonian brain. Short communication. J Neural Transm 1996, 103:1077-1081. 10.1007/BF01291792, 9013395.
3. Mogi M, Harada M, Narabayashi H, Inagaki H, Minami M, Nagatsu T. Interleukin (IL)-1 β, IL-2, IL-4, IL-6 and transforming growth factor-α are elevated in ventricular cerebrospinal fluid in juvenile Parkinsonism and Parkinson's disease. Neurosci Lett 1996, 211:13-16. 10.1016/0304-3940(96)12706-3, 8809836.
4. Bick RJ, Poindexter BJ, Kott MM, an Liang Y, Dinh K, Kaur B, Bick DLM, Doursout M-F, Schiess MC. Cytokines disrupt intracellular patterns of Parkinson's disease-associated proteins alpha-synuclein, tau, and ubiquitin in cultured glial cells. Brain Res 2008, 1217:203-212. 10.1016/j.brainres.2008.03.081, 18501880.
5. Clayton DF, George JM. The synucleins: a family of proteins involved in synaptic function, plasticity, neurodegeneration and disease. Trends Neurosci 1998, 21:249-254. 10.1016/S0166-2236(97)01213-7, 9641537.
6. Abeliovich A, Schmitz Y, Fariñas I, Choi-Lundberg D, Ho WH, Castillo PE, Shinsky N, Verdugo JM, Armanini M, Ryan A, Hynes M, Phillips H, Sulzer D, Rosenthal A. Mice lacking α-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron 2000, 25:239-252. 10.1016/S0896-6273(00)80886-7, 10707987.
7. Kubo S, Nemani VM, Chalkley RJ, Anthony MD, Hattori N, Mizuno Y, Edwards RH, Fortin DL. A combinatorial code for the interaction of α-Synuclein with membranes. J Biol Chem 2005, 280:31664-31672. 10.1074/jbc.M504894200, 16020543.
8. Olanow CW, Perl DP, DeMartino GN, StP McNaught K. Lewy-body formation is an aggresome-related process: a hypothesis. Lancet Neurol 2004, 3:496-503. 10.1016/S1474-4422(04)00827-0, 15261611.
9. Braak H, Del Tredici K, Rüb U, de Vos RAI. Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003, 24:197-211. 10.1016/S0197-4580(02)00065-9, 12498954.
10. Lee M, Schwab C, Yu S, McGeer E, McGeer PL. Astrocytes produce the anti-inflammatory and neuroprotective agent hydrogen sulfide. Neurobiol Aging 2009, 30:1523-1534. 10.1016/j.neurobiolaging.2009.06.001, 19631409.
11. Mrak RE. Neuropathology and neuroinflammation idea. J Alzheimers Dis 2009, 18:473-481.
12. Rossi D, Volterra A. Astrocytic dysfunction: insights on the role in neurodegeneration. Brain Res Bull 2009,
13. Braak H, Sastre M, Del Tredici K. Development of alpha-synuclein immunoreactive astrocytes in the forebrain parallels stages of intraneuronal pathology in sporadic Parkinson's disease. Acta Neuropatol 2007, 114:231-241.
14. Mandybur GT, Miyagi Y, Yin W, Perkins E, Zhang JH. Cytotoxicity of ventricular cerebrospinal fluid from Parkinson patients: correlation with clinical profiles and neurochemistry. Neurol Res 2003, 25:104-111. 10.1179/016164103101201021, 12564136.
15. Le WD, Rowe DB, Jankovic J, Xie W, Appel SH. Effects of cerebrospinal fluid from patients with Parkinson disease on dopaminergic cells. Arch Neurol 1999, 56:194-200. 10.1001/archneur.56.2.194, 10025424.
16. Hao R, Norgren RB, Lau YS, Pfeiffer RF. Cerebrospinal fluid of Parkinson's disease patients inhibits the growth and function of dopaminergic neurons in culture. Neurology 1995, 45:138-142.
17. Sugama S, Tekenouchi T, Cho BP, Joh TH, Hashimoto M, Kitani H. Possible role of microglial cells for neurotoxicity in clinical neurodegenerative disease and experimental animal models. Inflamm Allergy Drug Targets 2009, 8:277-284. 10.2174/187152809789352249, 19754411.
18. Yin GN, Jeon H, Lee S, Lee HW, Cho JY, Suk K. Role of soluble CD14 in cerebrospinal fluid as a regulator of glial functions. J Neurosci Res 2009, 87:2578-2590. 10.1002/jnr.22081, 19360901.
19. Emmanouilidoe E, Melachroinou K, Roumeliotis T, Garbis SD, Ntzouni M, Margaritis LH, Stefanis L, Vekrellis K. Cell-produced alpha-synuclein is secreted in a calcium-dependent manner by exosomes and impacts neuronal survival. J Neurosci 2010, 30:6838-6851. 10.1523/JNEUROSCI.5699-09.2010, 20484626.
20. Dinh K, Poindexter BJ, Barnes JL, Schiess MC, Bick RJ. Fluorescence microscopy and 3D image reconstruction of cytokine initiated disruption of the Parkinson disease associated proteins alpha-synuclein, tau and ubiquitin in cultured glial cells. Cytokine 2009, 45:179-183. 10.1016/j.cyto.2008.12.004, 19157893.
21. McGeer PL, McGeer EG. Glial reactions in Parkinson's disease. Mov Disord 2008, 23:474-483. 10.1002/mds.21751, 18044695.
22. Roodveldt C, Christodoulou J, Dobson CM. Immunological features of alpha-synuclein in Parkinson's disease. J Cell Mol Med 2008, 12:1820-1829.
23. Golovko MY, Barcelo-Coblijn G, Catagnet PI, Austin S, Combs CK, Murphy EJ. The role of alpha-synuclein in brain lipid metabolism: a downstream impact on the brain inflammatory response. Mol Cell Biochem 2009, 326:55-66. 10.1007/s11010-008-0008-y, 19116775.
24. Singleton A, Farrer M, Johnson J, Singleton A, Kachergus J, Hulihan M, Peuralinna T, Dutra A, Nussbaum R, Lincoln S, Crawley A, Hanson M, Maraganore D, Adler C, Cookson MR, Muenter M, Baptista M, Miller D, Blancato J, Hardy J, Gwinn-Hardy K. α-synuclein locus triplication causes Parkinson's disease. Science 2003, 302:841. 10.1126/science.1090278, 14593171.
25. Fuchs J, Tichopad A, Golub Y, Munz M, Schweitzer KJ, Wolf B, Berg D, Mueller JC, Gasser T. Genetic variability in the SNCA gene influences α-synuclein levels in the blood and brain. FASEB J 2008, 22:1327-1334. 10.1096/fj.07-9348com, 18162487.
26. Junn E, Mouradian MM. Human α-Synuclein over-expression increases intracellular reactive oxygen species levels and susceptibility to dopamine. Neurosci Lett 2002, 320:146-150. 10.1016/S0304-3940(02)00016-2, 11852183.
27. Yang Q, She H, Gearing M, Emanuela C, Lee M, Shacka JJ, Mao Z. Regulation of Neuronal Survival Factor MEF2D by Chaperone-Mediated Autophagy. Science 2009, 323:124-127. 10.1126/science.1166088, 2666000, 19119233.
28. Surguchov A. Molecular and cellular biology of synucleins. Int Rev Cell Mol Biol 2008, 270:225-317. full_text, 19081538.
29. Paleologou KE, Kragh CL, Mann DMA, Salem SA, Al-Shami R, Allsop D, Hassan AH, Jensen PH, Wl-Agnaf OMA. Detection of elevated levels of soluble α-synuclein oligomers in post-mortem brain extracts from patients with dementia with Lewy bodies. Brain 2009, 132:1093-1011. 10.1093/brain/awn349, 19155272.
30. Pierre SR, Lemmens MA, Figueiredo-Pereira ME. Subchronic infusion of the product of inflammation prostaglandin J2 models sporadic Parkinson's disease in mice. J Neuroinflammation 2009, 6:18-22. 10.1186/1742-2094-6-18, 2724408, 19630993.
31. Zheng J, Tang L, Zheng S, Zhan R, Zhou Y, Groudreau J, Kaufman D, Chen AF. Delayed gene therapy of glial cell line-derived neurotrophic factor is efficacious in a rat model of Parkinson's disease. Molec Brain Res 2005, 134:155-161. 10.1016/j.molbrainres.2004.06.029, 15790539.
32. Dowd E, Monville C, Torres EM, Wong L, Azzouz M, Mazarakis ND, Dunnett SB. Lentivector-mediated delivery of GDNF protects complex motor functions relevant to human Parkinsonism in a rat lesion model. Europe J of Neurosci 2005, 22:2587-2595.
33. Schiess MC, Zheng H, Soukup VM, Bonnen JG, Nauta JH. Parkinson's disease Subtypes: Clinical Classification and Ventricular Cerebrospinal Fluid (V-CSF) Analysis. Parkinsonism and Related Disorders (Elsevier) 2000, 6:69-76.
34. Wu HM, Tzeng NS, Qian L, Wei SJ, Hu X, Chen SH, Rawls SM, Flood P, Hong JS, Lu RB. Novel neuroprotective mechanisms of memantine: increase in neurotrophic factor release from astroglia and anti-inflammation by preventing microglial activation. Neuropsychopharm 2009, 34:2344-2357.
35. Poindexter BJ, Pereira-Smith OM, Smith JR, Buja LM, Bick RJ. 3-Dimensional reconstruction and localization of mortalin by deconvolution microscopy. Microsc Anal 2002, 89:21-23.